Gritstone bio, Inc. (GRTS)
- Previous Close
0.0520 - Open
0.0505 - Bid --
- Ask --
- Day's Range
0.0460 - 0.0513 - 52 Week Range
0.0460 - 3.1700 - Volume
33,856,646 - Avg. Volume
15,735,549 - Market Cap (intraday)
5.575M - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0900 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.75
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. On October 10, 2024, Gritstone bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
gritstonebio.comRecent News: GRTS
View MorePerformance Overview: GRTS
Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRTS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRTS
View MoreValuation Measures
Market Cap
5.57M
Enterprise Value
52.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.76
Price/Book (mrq)
0.25
Enterprise Value/Revenue
105.56
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.71%
Return on Equity (ttm)
-201.94%
Revenue (ttm)
14.61M
Net Income Avi to Common (ttm)
-133.03M
Diluted EPS (ttm)
-1.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
55.71M
Total Debt/Equity (mrq)
461.91%
Levered Free Cash Flow (ttm)
-66.16M